A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski, Daniel Rushing, Douglas Adkins, Scott H. Okuno, Gustavo Lorente, Stew Kroll, Virginia K. Langmuir, Sant P. Chawla

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics and preliminary activity of TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in patients with advanced soft tissue sarcoma. Patients and Methods: TH-302 was administered intravenously on days 1 and 8 and doxorubicin 75 mg/m2 on day 1 (2 h after TH-302) of every 3-week cycle. TH-302 starting dose was 240 mg/m2 with a classic 3 + 3 dose escalation. Pharmacokinetics were assessed on days 1 and 8 of cycle 1. Tumor assessments were performed after every second cycle. Results: Sixteen patients enrolled. Prophylactic growth factor support was added due to grade 4 neutropenia. The MTD was 300 mg/m2. DLTs at 340 mg/m2 were neutropenia-associated infection and grade 4 thrombocytopenia. Common adverse events included fatigue, nausea and skin rash. There was no evidence of pharmacokinetic interaction between TH-302 and doxorubicin. Five of 15 (33%) evaluable patients had a partial response by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Conclusions: The hematologic toxicity of doxorubicin is increased when combined with TH-302. This can be mitigated by prophylactic growth factor support. Toxicities were manageable and there was evidence of antitumor activity.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalOncology
Volume80
Issue number1-2
DOIs
StatePublished - Jun 2011

Fingerprint

Prodrugs
Sarcoma
Doxorubicin
Pharmacokinetics
Safety
Maximum Tolerated Dose
Neutropenia
Intercellular Signaling Peptides and Proteins
Exanthema
Nausea
Fatigue
Hypoxia
TH 302
Infection
Neoplasms

Keywords

  • Hypoxia-activated prodrug
  • Phase I clinical trial
  • Soft tissue sarcoma
  • TH-302

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. / Ganjoo, Kristen N.; Cranmer, Lee D.; Butrynski, James E.; Rushing, Daniel; Adkins, Douglas; Okuno, Scott H.; Lorente, Gustavo; Kroll, Stew; Langmuir, Virginia K.; Chawla, Sant P.

In: Oncology, Vol. 80, No. 1-2, 06.2011, p. 50-56.

Research output: Contribution to journalArticle

Ganjoo, KN, Cranmer, LD, Butrynski, JE, Rushing, D, Adkins, D, Okuno, SH, Lorente, G, Kroll, S, Langmuir, VK & Chawla, SP 2011, 'A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma', Oncology, vol. 80, no. 1-2, pp. 50-56. https://doi.org/10.1159/000327739
Ganjoo, Kristen N. ; Cranmer, Lee D. ; Butrynski, James E. ; Rushing, Daniel ; Adkins, Douglas ; Okuno, Scott H. ; Lorente, Gustavo ; Kroll, Stew ; Langmuir, Virginia K. ; Chawla, Sant P. / A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. In: Oncology. 2011 ; Vol. 80, No. 1-2. pp. 50-56.
@article{f63225bce36b46ffb2d7507e2aef8943,
title = "A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma",
abstract = "Purpose: The purpose of this study was to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics and preliminary activity of TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in patients with advanced soft tissue sarcoma. Patients and Methods: TH-302 was administered intravenously on days 1 and 8 and doxorubicin 75 mg/m2 on day 1 (2 h after TH-302) of every 3-week cycle. TH-302 starting dose was 240 mg/m2 with a classic 3 + 3 dose escalation. Pharmacokinetics were assessed on days 1 and 8 of cycle 1. Tumor assessments were performed after every second cycle. Results: Sixteen patients enrolled. Prophylactic growth factor support was added due to grade 4 neutropenia. The MTD was 300 mg/m2. DLTs at 340 mg/m2 were neutropenia-associated infection and grade 4 thrombocytopenia. Common adverse events included fatigue, nausea and skin rash. There was no evidence of pharmacokinetic interaction between TH-302 and doxorubicin. Five of 15 (33{\%}) evaluable patients had a partial response by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Conclusions: The hematologic toxicity of doxorubicin is increased when combined with TH-302. This can be mitigated by prophylactic growth factor support. Toxicities were manageable and there was evidence of antitumor activity.",
keywords = "Hypoxia-activated prodrug, Phase I clinical trial, Soft tissue sarcoma, TH-302",
author = "Ganjoo, {Kristen N.} and Cranmer, {Lee D.} and Butrynski, {James E.} and Daniel Rushing and Douglas Adkins and Okuno, {Scott H.} and Gustavo Lorente and Stew Kroll and Langmuir, {Virginia K.} and Chawla, {Sant P.}",
year = "2011",
month = "6",
doi = "10.1159/000327739",
language = "English",
volume = "80",
pages = "50--56",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1-2",

}

TY - JOUR

T1 - A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

AU - Ganjoo, Kristen N.

AU - Cranmer, Lee D.

AU - Butrynski, James E.

AU - Rushing, Daniel

AU - Adkins, Douglas

AU - Okuno, Scott H.

AU - Lorente, Gustavo

AU - Kroll, Stew

AU - Langmuir, Virginia K.

AU - Chawla, Sant P.

PY - 2011/6

Y1 - 2011/6

N2 - Purpose: The purpose of this study was to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics and preliminary activity of TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in patients with advanced soft tissue sarcoma. Patients and Methods: TH-302 was administered intravenously on days 1 and 8 and doxorubicin 75 mg/m2 on day 1 (2 h after TH-302) of every 3-week cycle. TH-302 starting dose was 240 mg/m2 with a classic 3 + 3 dose escalation. Pharmacokinetics were assessed on days 1 and 8 of cycle 1. Tumor assessments were performed after every second cycle. Results: Sixteen patients enrolled. Prophylactic growth factor support was added due to grade 4 neutropenia. The MTD was 300 mg/m2. DLTs at 340 mg/m2 were neutropenia-associated infection and grade 4 thrombocytopenia. Common adverse events included fatigue, nausea and skin rash. There was no evidence of pharmacokinetic interaction between TH-302 and doxorubicin. Five of 15 (33%) evaluable patients had a partial response by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Conclusions: The hematologic toxicity of doxorubicin is increased when combined with TH-302. This can be mitigated by prophylactic growth factor support. Toxicities were manageable and there was evidence of antitumor activity.

AB - Purpose: The purpose of this study was to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics and preliminary activity of TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in patients with advanced soft tissue sarcoma. Patients and Methods: TH-302 was administered intravenously on days 1 and 8 and doxorubicin 75 mg/m2 on day 1 (2 h after TH-302) of every 3-week cycle. TH-302 starting dose was 240 mg/m2 with a classic 3 + 3 dose escalation. Pharmacokinetics were assessed on days 1 and 8 of cycle 1. Tumor assessments were performed after every second cycle. Results: Sixteen patients enrolled. Prophylactic growth factor support was added due to grade 4 neutropenia. The MTD was 300 mg/m2. DLTs at 340 mg/m2 were neutropenia-associated infection and grade 4 thrombocytopenia. Common adverse events included fatigue, nausea and skin rash. There was no evidence of pharmacokinetic interaction between TH-302 and doxorubicin. Five of 15 (33%) evaluable patients had a partial response by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Conclusions: The hematologic toxicity of doxorubicin is increased when combined with TH-302. This can be mitigated by prophylactic growth factor support. Toxicities were manageable and there was evidence of antitumor activity.

KW - Hypoxia-activated prodrug

KW - Phase I clinical trial

KW - Soft tissue sarcoma

KW - TH-302

UR - http://www.scopus.com/inward/record.url?scp=79957544947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957544947&partnerID=8YFLogxK

U2 - 10.1159/000327739

DO - 10.1159/000327739

M3 - Article

C2 - 21625179

AN - SCOPUS:79957544947

VL - 80

SP - 50

EP - 56

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1-2

ER -